Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DSM and Crucell have reported fermentation yields of more than 10 grams per liter for monoclonal antibodies, a major breakthrough in the development of their PER.C6 technology platform.
Subscribe to our email newsletter
The companies believes this is a major breakthrough in reducing the cost of goods in biopharmaceutical production
A key objective of their development venture was to achieve yields of more than 10 grams per liter for monoclonal antibodies using the PER.C6 technology platform. Crucell’s and DSM’s PER.C6 technology platform is developed for the large-scale manufacture of biopharmaceutical products including vaccines.
The parties believe that in the foreseeable future even 20 grams per liter can be realized. Yields in the range of 10 to 20g/L are an order of magnitude higher than current industry averages. The higher yields allow the use of much smaller bio-reactors and opens routes to significantly lower cost of goods for biopharmaceuticals.
“We believe that these results mark the beginning of a paradigm shift in the industry,” commented Leendert Staal, CEO of DSM Pharmaceutical Products
Crucell said the next steps will be to upgrade to pilot scale and ultimately commercial scale reactors.